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Abstract
Background: Cannabis sativa (also known as marijuana) has been cultivated by man for more than 5,000 years.
However, there was a rise in its use in the 20
th century for recreational, religious or spiritual, and medicinal
purposes. The main psychoactive constituent of cannabis, whose structure was identified in the 1960’s, is Δ
9-
tetrahydrocannabinol. On the other hand, the discovery of cannabinoid receptors and their endogenous agonists
took place only very recently. In fact, the first cannabinoid receptor (CB1) was cloned in 1990, followed 3 years later
by the characterization of a second cannabinoid receptor (CB2). Since the 19
th century, the use of cannabis has
been reported to stimulate appetite and increase the consumption of sweet and tasty food, sometimes resulting in
significant weight gain. The recent description of the endocannabinoid system, not only in the central nervous
system but also in peripheral tissues, points to its involvement in the regulation of appetite, food intake and
energy metabolism. Consequently, the pharmacological modulation of the over-activity of this system could be
useful in the treatment of the metabolic syndrome.
Conclusions: The endocannabinoid system has important physiological functions not only in the central nervous
system but also in peripheral tissues. The activation of central CB1 receptors, particularly in hypothalamic nuclei and
in the limbic system, is involved in the regulation of feeding behavior, and especially in the control of the intake of
palatable food. In the periphery, cannabinoid receptors are present in adipocytes, skeletal muscle, gastrointestinal
tract and liver, modulating energy metabolism.
Introduction
Historical aspects
Cannabis sativa (marijuana or cannabis) has been culti-
vated by man since approximately 4,000 B.C [1,2]. At
that time, the fibers obtained from the cannabis stems
were mainly used to manufacture textiles and paper [1].
Moreover, from that time on, cannabis has also been
known to have a variety of medicinal effects unrelated
to its psychoactive properties, including effects on anor-
exia, emesis, pain, inflammation and neurodegenerative
disorders [3]. Cannabis is the most widely used illicit
drug in Western societies and also the one with the
longest recorded history of human use. The popularity
of marijuana as a recreational drug is due to its ability
to alter sensory perception and cause elation and
euphoria [2].
It has also been known since 300 B.C. that the recrea-
tional use of cannabis stimulates appetite, especially for
sweet and palatable food [4,5]. Nevertheless, this phe-
nomenon was seriously taken into consideration in bio-
medical research only in the last decade, after the
description of the existence of an endogenous cannabi-
noid system [6,7], providing a physiological basis for the
biological effects induced by cannabis and its derivatives.
Several chemical constituents of cannabis have already
been identified, but its main psychoactive constituent is
considered to be Δ
9-tetrahydrocannabinol (Δ
9-THC),
whose structure was identified in the 1960’s[ 8 ] .E v e n
though several naturally-occurring agonists of the endo-
genous cannabinoid system have been known since
then, the discovery of cannabinoid receptors and their
endogenous agonists took place only very recently. In
fact, the first cannabinoid receptor (CB1) was cloned in
1990 [9], followed 3 years later by the characterization
of a second cannabinoid receptor (CB2) [10]. * Correspondence: etibi@ioc.fiocruz.br
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Cannabinoid receptors belong to the G protein-coupled
receptor superfamily and their activation modulates ade-
nylate-cyclase, potassium and calcium channels and
transcription factors such as mitogen-activated protein
kinase [6,11]. The CB1 cannabinoid receptor is widely
expressed in the central nervous system as well as in the
periphery, while CB2 is mainly expressed in immune
cells. In the central nervous system, CB1 is predomi-
nantly expressed presynaptically, modulating the release
of neurotransmitters, including g-aminobutyric acid
(GABA), dopamine, noradrenaline, glutamate and sero-
tonin [12].
The discovery of specific receptors mediating the
actions of cannabis led to the search for endogenous
ligands for cannabinoid receptors. The first endogenous
cannabinoid, arachidonoyl ethanolamide, was identified
in 1992 and was named anandamide, from the Sanskrit
word ‘ananda’, meaning internal ecstasy [13,14]. Thus,
both plant-derived (Δ
9-THC) and endogenous (ananda-
mide) agonists bind to the same cannabinoid receptors
( F i g u r e1 ) .S i n c et h ed i s c o v e r yo fa n a n d a m i d e ,o t h e r
polyunsaturated fatty acid derivatives acting as func-
tional agonists of cannabinoid receptors have been char-
acterized and collectively termed endocannabinoids [15].
In contrast to classical neurotransmitters such as the
catecholamines, endocannabinoids are not stored in the
interior of synaptic vesicles because of the high lipophi-
licity of these ligands [6]. These findings led to the con-
clusion that the endocannabinoid system acts “on
demand”, meaning that the endocannabinoids are
synthesized and released upon physiological or patholo-
gical stimulation [6].
The endocannabinoid system and the regulation of food
intake and energy metabolism
Since the 19
th century the use of cannabis has been
reported to stimulate appetite and to increase the con-
sumption of sweet and tasty food, sometimes resulting
in significant weight gain [4,16]. The recent description
of the endocannabinoid system, not only in the central
nervous system but also in peripheral tissues, points to
its involvement in the regulation of appetite, food intake
and energy metabolism [17-20]. Numerous experimental
data have confirmed this hypothesis and will be briefly
summarized below, while clinical results will be pre-
sented in the next topic of this article.
Endocannabinoid actions in the central nervous system
It has already been demonstrated that endocannabinoids
initiate appetite by stimulation of CB1 receptors in
hypothalamic areas involved in the control of food
intake, such as the ventromedial hypothalamus (VMH)
[21] (Figure 2). For instance, the injection of
anandamide in the VMH of pre-satiated rats induces
hyperphagia, which is prevented by previous hypothala-
mic administration of the selective CB1 cannabinoid
antagonist rimonabant [22]. Using another experimental
approach, Kirkham et al. [23] evaluated endocannabi-
noid levels in relation to the feeding behavior of rats in
the hypothalamus and in the limbic forebrain, including
the shell area of the nucleus accumbens, which is
known to be linked to eating motivation. Endocannabi-
noid levels increased during fasting and declined during
feeding, while no changes were detected in satiated rats.
On the other hand, endocannabinoid levels in the cere-
bellum, which is not directly involved in the control of
food intake, were unaffected by feeding behavior. More-
over, the injection of endocannabinoids into the nucleus
accumbens induced feeding behavior, an effect that was
also attenuated by rimonabant [23].
The experimental model of CB1 receptor knockout
(CB1-/-) mice has also been used to clarify the involve-
ment of the endocannabinoid system in the regulation
of energy metabolism. An elegant study conducted by
Ravinet-Trillou et al. compared CB1-/- knockout male
mice with wild-type animals (CB1+/+) exposed either to
a standard laboratory regimen or to a high-fat diet
(HFD) [24]. When maintained on the standard diet,
CB1-/- mice are lean and their body weight and adipos-
ity are, respectively, 24 and 60% lower than that of CB1
+/+ mice. CB1-/- mice submitted to the HFD do not
develop obesity and do not display hyperphagia in con-
trast to CB1+/+ mice, and their feeding efficiency
remains low. Furthermore, the insulin resistance that
occurs in HFD-fed mice is not present in CB1-/- mice.
These results led to the conclusion that CB1 receptors
are involved not only in the development of diet-
induced obesity but also in peripheral metabolic regula-
tions [24]. These results were confirmed by Cota et al.
[25], who showed that CB1-/- mice exhibit reduced
spontaneous caloric intake and total fat mass, decreased
body weight, and hypophagia, when compared with CB1
+/+ littermates. Moreover, in young CB1-/- mice, the
lean phenotype is predominantly caused by decreased
caloric intake, whereas in adult CB1-/- mice, metabolic
factors appear to contribute to the lean phenotype [25].
Another study carried out in mice submitted to HFD
showed that a short-lasting reduction of food intake
induced by a chronic oral treatment with rimonabant is
dissociated from the long-lasting reduction of body weight
and obesity. Moreover, rimonabant reverses the insulin
resistance and lowered plasma leptin, insulin, and free
fatty acid levels in this model of diet-induced obesity [26].
It is also noteworthy that Δ
9-THC increases not only
total food intake but also specifically increases the con-
sumption of sweets, suggesting an interaction between
the effect of the drug and the palatability of the food
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ing that different routes of Δ
9-THC administration (oral,
smoke inhalation or suppository) induced an effect on
food selection [28]. Moreover, this selective action on
food choice was confirmed in a number of animal stu-
dies, in which a potential role of cannabinoids in modu-
lating the interaction of different pathways involved in
the brain ‘reward’ system was hypothesized [29,30].
Thus, endocannabinoid signaling is involved orexigeni-
cally in both the homeostatic and the hedonistic control
of food intake [31].
Endocannabinoid actions in the periphery
Adipocytes
Af u n c t i o n a lC B 1 receptor has already been identified in
the fat tissue of rodents [25]. The CB1 receptor is
expressed both in epididymal fat pads extracted from
mice and in primary adipocyte cell cultures and seems
to be involved in the regulation of lipogenesis. More-
over, the receptor is expressed in fat tissue obtained
from CB1+/+,b u tn o tC B 1-/- knockout, mice. CB1 ago-
nists dose-dependently increase lipoprotein lipase activ-
ity in adipocyte cell cultures, and this effect can be
blocked by the preincubation with the CB1 selective
antagonist rimonabant, thus confirming a specific can-
nabinoid mechanism of action [25].
Interestingly, the blockade of CB1 receptors, either in
vivo or in adipocyte cell cultures, results in a significant
increase of adiponectin production [32]. Adiponectin is
secreted exclusively by adipose tissue, with plasma levels
negatively correlated with obesity [33]. Moreover, adipo-
nectin is the only adipocytokine with anti-inflammatory
effects and with a protective role against atherosclerosis,
in addition to its insulin sensitizer effect [34]. The mod-
ulation of the endocannabinoid system using a chronic
oral treatment with rimonabant simultaneously reduces
body weight and stimulates adiponectin mRNA expres-
sion in adipose tissue of obese Zucker rats [32]. In par-
allel, the hyperinsulinemia associated with this
experimental model was reduced by rimonabant
Figure 1 Both Δ
9-tetrahydrocannabinol, the psychoactive component of Cannabis sativa, and anandamide, an endogenous
neurotransmitter in the human brain, bind to the same cannabinoid receptor. (Photos/Diagrams from the Max Planck Institute of
Psychiatry [42]).
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regulated by the blockade of CB1 receptors only in CB1
+/+, but not CB1-/- knockout, mice [32].
Skeletal muscle
It has already been shown that the modulation of the
endocannabinoid system regulates glucose uptake
through the phosphatidylinositol-3-kinase pathway in
skeletal muscle cells [35]. Accordingly, the blockade of
peripheral CB1 receptors could contribute to the
improvement of glycemia observed in clinical trials with
rimonabant [36]. In this context, Liu et al. clearly
demonstrated that a sub-acute treatment with rimona-
bant increases soleus muscle glucose uptake in leptin-
deficient obese mice [37].
Liver
T h ep r e s e n c eo fC B 1 receptors in the mouse liver has
been confirmed using multiple methodological
approaches [38], indicating that the hepatocyte could be
Figure 2 The involvement of the endocannabinoid (EC) system over-activity in the pathophysiology of the metabolic syndrome.
Adapted from [20] and [17].
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system. In fact, the activation of the CB1 receptor
increases the expression of lipogenic genes in the liver,
which is the main source of de novo fatty acid synthesis
in the body [38].
Synthetic agonists of the CB1 receptor induce the
expression of several key lipogenic enzymes in liver, an
effect that is prevented by a pretreatment with CB1
receptor antagonists [38]. Moreover, the basal rates of
de novo fatty acid synthesis are markedly increased in
CB1+/+ m i c es u b m i t t e dt oah i g hf a td i e t( H F D ) ,c o m -
pared with those of lean controls, but not in the CB1-/-
knockout mice [38]. The pretreatment of CB1+/+ mice
on HFD with a CB1 receptor antagonist reduces the rate
of fatty acid synthesis [38]. In mice on HFD, the hepatic
levels of the endocannabinoid anandamide were also
greatly elevated. Finally, a marked deposition of lipid
droplets was evident in wild-type, but not CB1-/- mice
on HFD [38], suggesting the involvement of cannabinoid
activation in liver steatosis.
Conclusions
The endocannabinoid system is present and has impor-
tant physiological functions not only in the central ner-
vous system but also in peripheral tissues. The
activation of central CB1 receptors, particularly in
hypothalamic nuclei and in the limbic system, is
involved in the regulation of feeding behavior, and espe-
cially in the control of the intake of palatable food. It is
important to mention that the activation of the endo-
cannabinoid system, in addition to increasing appetite
(total food intake), also influences the palatability and
the preferential choice of tasty and sweet foods [5] (Fig-
ure 2). Thus, endocannabinoid antagonists could be uti-
lized for the treatment of the type of obesity associated
with specific eating disorders such as ‘sweet and snack-
eating’ and compulsive eating episodes.
In the periphery, cannabinoid receptors are present in
adipocytes, skeletal muscle, gastrointestinal tract and
liver, modulating energy metabolism (Table 1).
In conclusion, the endocannabinoid system seems to
play a key role in the development and maintenance of
obesity (see previous reviews [5,39,40]). In obese
patients, excessive food intake, especially of sweet and
palatable food, could lead to the hyperactivity of the
endocannabinoid system, resulting in several metabolic
alterations typical of the metabolic syndrome (Figure 1).
Thus, the pharmacological modulation of the endocan-
nabinoid system turns out to be a unique target in the
treatment of those that are overweight or obese [41].
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